Adeona partners Intrexon in stock-for-tech deal for pulmonary arterial hypertension
This article was originally published in Scrip
Executive Summary
Adeona Pharmaceuticals, a development firm that does not have its own in-house R&D, has entered into a global collaboration with the synthetic biology company Intrexon whereby Adeona hopes to develop and commercialise a DNA-based treatment for pulmonary arterial hypertension (PAH). Adeona is 'buying' access to Intrexon's technology with its stock.